833 related articles for article (PubMed ID: 29056344)
1. Comprehensive Analysis of Hypermutation in Human Cancer.
Campbell BB; Light N; Fabrizio D; Zatzman M; Fuligni F; de Borja R; Davidson S; Edwards M; Elvin JA; Hodel KP; Zahurancik WJ; Suo Z; Lipman T; Wimmer K; Kratz CP; Bowers DC; Laetsch TW; Dunn GP; Johanns TM; Grimmer MR; Smirnov IV; Larouche V; Samuel D; Bronsema A; Osborn M; Stearns D; Raman P; Cole KA; Storm PB; Yalon M; Opocher E; Mason G; Thomas GA; Sabel M; George B; Ziegler DS; Lindhorst S; Issai VM; Constantini S; Toledano H; Elhasid R; Farah R; Dvir R; Dirks P; Huang A; Galati MA; Chung J; Ramaswamy V; Irwin MS; Aronson M; Durno C; Taylor MD; Rechavi G; Maris JM; Bouffet E; Hawkins C; Costello JF; Meyn MS; Pursell ZF; Malkin D; Tabori U; Shlien A
Cell; 2017 Nov; 171(5):1042-1056.e10. PubMed ID: 29056344
[TBL] [Abstract][Full Text] [Related]
2. Germline
Lindsay H; Scollon S; Reuther J; Voicu H; Rednam SP; Lin FY; Fisher KE; Chintagumpala M; Adesina AM; Parsons DW; Plon SE; Roy A
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31624068
[TBL] [Abstract][Full Text] [Related]
3. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
[TBL] [Abstract][Full Text] [Related]
4. POLE/POLD1 mutation and tumor immunotherapy.
Ma X; Dong L; Liu X; Ou K; Yang L
J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
[TBL] [Abstract][Full Text] [Related]
5. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
[TBL] [Abstract][Full Text] [Related]
6. Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer.
Yoshida R; Miyashita K; Inoue M; Shimamoto A; Yan Z; Egashira A; Oki E; Kakeji Y; Oda S; Maehara Y
Eur J Hum Genet; 2011 Mar; 19(3):320-5. PubMed ID: 21157497
[TBL] [Abstract][Full Text] [Related]
7. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
8. Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair.
Haradhvala NJ; Kim J; Maruvka YE; Polak P; Rosebrock D; Livitz D; Hess JM; Leshchiner I; Kamburov A; Mouw KW; Lawrence MS; Getz G
Nat Commun; 2018 May; 9(1):1746. PubMed ID: 29717118
[TBL] [Abstract][Full Text] [Related]
9. The burden of faulty proofreading in colon cancer.
Seshagiri S
Nat Genet; 2013 Feb; 45(2):121-2. PubMed ID: 23358219
[TBL] [Abstract][Full Text] [Related]
10. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
[TBL] [Abstract][Full Text] [Related]
11. POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX; Wang ZX; Yuan SQ; Jiang TJ; Huang YS; Xu RH; Wang F; Zhao Q
Clin Transl Med; 2021 Sep; 11(9):e524. PubMed ID: 34586735
[No Abstract] [Full Text] [Related]
12. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
[TBL] [Abstract][Full Text] [Related]
13. POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.
Rosner G; Gluck N; Carmi S; Bercovich D; Fliss-Issakov N; Ben-Yehoyada M; Aharon-Caspi S; Kellerman E; Strul H; Shibolet O; Kariv R
Dis Colon Rectum; 2018 Sep; 61(9):1073-1079. PubMed ID: 30086056
[TBL] [Abstract][Full Text] [Related]
14. Human Pol ε-dependent replication errors and the influence of mismatch repair on their correction.
Agbor AA; Göksenin AY; LeCompte KG; Hans SH; Pursell ZF
DNA Repair (Amst); 2013 Nov; 12(11):954-63. PubMed ID: 24051051
[TBL] [Abstract][Full Text] [Related]
15. POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies.
Nicolas E; Golemis EA; Arora S
Gene; 2016 Sep; 590(1):128-41. PubMed ID: 27320729
[TBL] [Abstract][Full Text] [Related]
16. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.
Ma X; Riaz N; Samstein RM; Lee M; Makarov V; Valero C; Chowell D; Kuo F; Hoen D; Fitzgerald CWR; Jiang H; Alektiar J; Alban TJ; Juric I; Parthasarathy PB; Zhao Y; Sabio EY; Verma R; Srivastava RM; Vuong L; Yang W; Zhang X; Wang J; Chu LK; Wang SL; Kelly DW; Pei X; Chen J; Yaeger R; Zamarin D; Zehir A; Gönen M; Morris LGT; Chan TA
Nat Genet; 2022 Jul; 54(7):996-1012. PubMed ID: 35817971
[TBL] [Abstract][Full Text] [Related]
17. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.
Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F
Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678
[TBL] [Abstract][Full Text] [Related]
18. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response.
Li HD; Lu C; Zhang H; Hu Q; Zhang J; Cuevas IC; Sahoo SS; Aguilar M; Maurais EG; Zhang S; Wang X; Akbay EA; Li GM; Li B; Koduru P; Ly P; Fu YX; Castrillon DH
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32699191
[TBL] [Abstract][Full Text] [Related]
19. The interaction between cytosine methylation and processes of DNA replication and repair shape the mutational landscape of cancer genomes.
Poulos RC; Olivier J; Wong JWH
Nucleic Acids Res; 2017 Jul; 45(13):7786-7795. PubMed ID: 28531315
[TBL] [Abstract][Full Text] [Related]
20. Development of an MSI-positive colon tumor with aberrant DNA methylation in a PPAP patient.
Yamaguchi K; Shimizu E; Yamaguchi R; Imoto S; Komura M; Hatakeyama S; Noguchi R; Takane K; Ikenoue T; Gohda Y; Yano H; Miyano S; Furukawa Y
J Hum Genet; 2019 Aug; 64(8):729-740. PubMed ID: 31089268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
